Remove Clinical Supply Chain Remove Gene Therapy Remove Production
article thumbnail

Untangling the Complexities of Cell and Gene Therapy Clinical Trials: A Supply Chain Perspective 

Pharmaceutical Technology

By Luisa Sterkel & Joana Loureiro , Tenthpin Consultants The promise and potential of cell and gene therapies (CGT) has emerged in the recent past and currently over 1.500 CGT are registered for clinical trials holding great hope for the treatment of challenging and uncurable diseases.

article thumbnail

Why demand is rising for secure and climate-controlled gene therapy services

Pharmaceutical Technology

Although only a small number of gene therapies have reached the market thus far, the industry is poised to grow quickly over the next few years. According to GlobalData’s clinical trials database, there are currently 1,231 planned and ongoing trials for gene therapies and gene-modified cell therapies alone.

article thumbnail

Keeping tabs on Covid-19: BioNTech buys GMP-certified facility to boost vaccine…

The Pharma Data

BioNTech acquires Novartis GMP manufacturing site to expand Covid-19 vaccine production. BioNTech has agreed to buy a Novartis manufacturing facility in Marbury, Germany, to expand its Covid-19 vaccine production capacity by up to 750 million doses per year, or more than 60 million doses per month, once fully operational.